Introduction
Malignancy of the uterine corpus is the fourth most common cancer in women living in developed countries worldwide. Endometrial Stromal Sarcoma (ESS) is a rare neoplasm comprising only 0.2% of all uterine malignancies and 15e26% of primary uterine sarcomas with less than 700 cases diagnosed annually. 1 ESS was formerly classified into two distinct subtypes, low-grade and highgrade, based on differences in morphological atypia and proliferative activity. The World Health Organization (WHO) re-classified these entities into three groups: benign endometrial stromal nodule (ESN), low-grade endometrial stromal sarcoma (LGESS), and undifferentiated endometrial sarcoma (UES). 2 LGESS is a slow growing tumor with good prognosis and a 50% recurrence following treatment. Common metastatic sites for LGESS are the vagina, pelvis, and peritoneal cavity although distant metastasis to sigmoid colon, lung, liver, brain, has also been reported. 3 We present a case of low-grade ESS that recurred 14 years following the original surgery with metastasis in the retroperitoneal.
Case presentations
A 72-year-old woman presented with dyspnea and bilateral peripheral edema. She had undergone total hysterectomy for low-grade endometrial stromal sarcoma (LGESS) tumor fourteen years prior, which was confirmed histologically to be LGESS. There were no significant past medical history or history of familial disease. Physical examination showed palpable abdominal mass at the Right Lower Quadrant and Left Lower Quadrant. The following tumor markers (AFP, CEA, Cancer Antigen 125, and BhCG) are within reference limits. Yet, normal results do not exclude neoplasia. CT scan of the abdomen and pelvis revealed presence of several retroperitoneal masses surrounding the abdominal aorta and vena cava (Fig. 1 ). Percutaneous biopsy of the lesion showed diffuse proliferation of spindle-shaped cells with little nuclear atypia. Morphologically, the tumor resembles the tumor from the 1993 histopathology specimen.
The patient underwent a laparotomy and excision of all tumor nodules. Seven nodular masses were excised weighing altogether 1042 g (Fig. 2) . The largest nodule measured 160 Â 100 Â 80 mm in dimension (Fig. 3) and the smallest was 20 x 20 Â 12 mm. The largest nodule impinges upon the right ureter, right kidney and iliac vessels. The external surfaces of all these nodules appear lobulated, multinodular, and covered by a serosal surface that formed a capsule. This enabled easy excision during surgery.
The patient's postoperative course was uneventful. She was free of symptoms 2 weeks following abdominal surgery.
Discussion
Clinical characteristics of low-grade ESS (LGESS) include a slow growth and indolent disease course with a tendency for late recurrence. A study by Piver et al reported that the intervals before recurrence varied from 3 months to 23 years, with a median interval of 3 years. 50% of patients with low-grade ESS develop recurrences or metastases in the vagina, pelvis, and peritoneal cavity although distant metastasis has been reported. 4 Although outdated, ESS was formerly classified into low-grade ESS and high-grade ESS based on differences in the cell's mitotic activity. More than 10 mitotic figures for high-grade ESS and less than 10 mitotic figures per 10 HPF for low-grade ESS. Microscopic examination of the tumor showed that it has mitotic count less than 10 in mitosis per high power fields (HPF) e thus classifying the tumor as low-grade ESS rather than high-grade ESS.
Surgical excision is currently the only therapeutic procedure for LGESS. Standard treatment for its recurrent disease such as radiotherapy and chemotherapy has not been established to be effective. Immunoreactivity for estrogen receptor and progesterone receptor is not regularly assessed in LGESS. Based on several clinical studies, Mansi et al recommended that progesterone therapy should be the treatment of first choice for relapsed LGESS because there was resolution or stabilization of recurrent or metastatic disease in more than 50% of patients treated with progestational agents. 5 This suggestion is noteworthy since our tumor sample showed strong and diffuse staining against anti-estrogen and progesterone receptor antibodies.
Conclusion
Considering the slow growing nature and common recurrence of LGESS, 14 years' recurrences in this case, a life-long follow up and routine assessment for anti-estrogen and anti-progesterone should be integrated into clinical practice in LGESS management. Any sign of recurrence should be managed with surgical excision.
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